title: [Metronomic chemotherapy. Should we change our thinking in the treatment of advanced tumors?].
authors.forename: Cornelia
authors.initials: C
authors.lastname: Mauch
mesh_terms: D000284:Administration, Oral; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy; D002066:Busulfan / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005544:Forecasting; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D011446:Prospective Studies; D011788:Quality of Life; D012878:Skin Neoplasms / Q000188:drug therapy; D013997:Time Factors; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D052246:Cyclooxygenase 2 Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D003520:Cyclophosphamide; C018404:treosulfan; D002066:Busulfan; C003726:trofosfamide